Company Overview of Nestlé Health Science S.A.
Nestlé Health Science S.A. develops science-based personalized nutritional solutions for ageing, paediatric, critical care, surgery, gastrointestinal, diabetes, obesity, and oncology care in Switzerland and internationally. It offers Alfaré, an infant formula for infants suffering from severe and chronic diarrhoea, malabsorption, and malnutrition; Althéra, an infant formula for infants suffering from food protein allergy; Boost, a nutritional drink for daily nutritional needs of adults; Boost Glucose Control for people with type 2 diabetes; Boost Kid Essentials, a drink designed for children ages 1-10; Carnation Breakfast Essentials, which provide the nutrition of a breakfast; and Diabetisou...
avenue Nestlé 55
Founded in 2011
Key Executives for Nestlé Health Science S.A.
Director and Chief Executive Officer of Nestlé S A
Chief Executive Officer of Accera and President of Accera
Head of Nestlé Institute of Health Sciences and Director
Compensation as of Fiscal Year 2013.
Nestlé Health Science S.A. Key Developments
Nestlé Health Science S.A. and Moog Inc. announce North American Exclusive distribution Agreement for EnteraLite(R) Infinity(R) Pump
Feb 22 13
Nestlé Health Science S.A. and Moog Inc. announced that effective immediately Nestle Health Science will become the exclusive distributor in the U.S. and Canada for Moog's EnteraLite(R) Infinity(R) Pump, including compatible administration sets and accessories. The agreement between Nestle Health Science and Moog expands availability of a enteral delivery system that can be used across the full continuum of care -- for adult and pediatric patients in the hospital and at home. Working together, both companies are now well positioned to meet the needs of hospital, home care and other alternate site customers.
Nestlé Health Science S.A. and Hutchison China MediTech Ltd. Establishes Joint Venture
Nov 28 12
Nestle´ Health Science SA and Hutchison China MediTech Ltd. announced that they have agreed to form a 50/50 joint venture to be named Nutrition Science Partners Limited. The purpose of NSP is to research, develop, manufacture and market worldwide novel medicines and nutritional products derived from botanical plant origins. NSP will focus on gastrointestinal indications, and may in the future expand into the metabolic disease and brain health areas. Nestlé Health Science will make an initial capital investment in return for its 50% shareholding in NSP; while Chi-Med will provide exclusive rights to its extensive botanical library and well-established botanical R&D platform, in the field of gastrointestinal disease. Such botanical library contains over 1,500 purified natural products and over 50,000 extracts/fractions derived from more than 1,200 different medicinal plants.
Nestlé Health Science S.A. Announces the Availability of Resource(R) ThickenUp(R) Clear
Jun 11 12
Nestlé Health Science S.A. announced the availability of Resource(R) ThickenUp(R) Clear, an innovative, non-starch-based thickening powder. This product is designed to decrease the risk of aspiration compared to thin liquids for people with dysphagia -- a serious condition affecting nearly 25 million people in the U.S.(1,2) Designed to address the challenges of some existing starch-based thickeners, Resource(R) ThickenUp(R) Clear is tasteless, mixes and dissolves easily and remains clear when mixed with water. Some people affected by dysphagia (swallowing difficulties) may require the texture of liquids and foods to be modified with a thickening product in order to help them swallow more safely. Thickening products are designed to assist patients with swallowing function by helping to keep foods and liquids from entering the lungs. A recent study conducted by Rebecca J. Leonard, Ph.D., showed a significant reduction in the incidence of penetration and aspiration in dysphagia patients who consumed Resource(R) ThickenUp(R) Clear, made with xanthan gum, compared to thin liquid. Improvement in airway closure time was observed for gum-thickened barium compared to thin liquid barium, demonstrating the ability of this new gum-based thickener to enhance dysphagia patient safety. Nestle Health Science recommends systematic screening to identify individuals at risk of dysphagia and help improve outcomes by implementing the validated dysphagia screening tool EAT-10 as a standard of care. Patients identified at risk for dysphagia should then be referred to a speech language pathologist for further evaluation, dietary modifications and treatment, as needed. To assist clinicians in the diagnosis and management of dysphagia patients Nestle Health Science has developed a variety of resources and products.
Similar Private Companies By Industry
Recent Private Companies Transactions